Fulltext

Trends in survival for patients diagnosed with cancer in Vaud, Switzerland, between 1974 and 1993

Levi, F. ; Randimbison, L. ; Te, V.-C ; Franceschi, S. ; La Vecchia, C.

In: Annals of Oncology, 2000, vol. 11, no. 8, p. 957-963

Aggiungi alla tua lista
    Titre
    • Trends in survival for patients diagnosed with cancer in Vaud, Switzerland, between 1974 and 1993
    Auteur
    • Levi, F.. Registre Vaudois des Tumeurs, Institut Universitaire de Médecine Sociale et Préventive, Centre Hospitalier Unirersitaire Vaudois Lausanne, Switzerland
    • Randimbison, L.. Unité d'Épidémologie du Cancer, Institut Universitaire de Médecine Sociale et Préventive Lausanne, Switzerland
    • Te, V.-C. Registre Vaudois des Tumeurs, Institut Universitaire de Médecine Sociale et Préventive, Centre Hospitalier Unirersitaire Vaudois Lausanne, Switzerland
    • Franceschi, S.. Servizio di Epidemiologia, Centro di Riferimento Oncologico Aviano (PN)
    • La Vecchia, C.. Istituto di Ricerche Farmacologiche Mario Negri
    Type de document
    • Postprint
    Langue
    • Inglese
    Publié dans
    • Annals of Oncology, 2000, vol. 11, no. 8, p. 957-963. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:296193
    Summary
    Background Analysis of trends in cancer survival in defined well surveilled populations can provide useful indications on advancements in cancer management and treatment. Patients and methods Survival rates from the Vaud Cancer Registry were computed for 31,158 cases registered in 1984-1993, and compared with those registered in 1974-1978 and 1979-1983. Results A systematic, albeit generally moderate, tendency towards increasing five-year relative survival was observed for both sexes and most major cancer sites, including oral cavity and pharynx (0.38-0.43), stomach (0.21-0.26), colon (0.49-0.55), rectum (0.45-0.51), lung (0.08-0.12), skin melanoma (0.67-0.89), female breast (0.67-0.80), endometrium (0.72-0.84), ovary (0.28-0.37), prostate (0.44-0.66), testis (0.73-0.96), bladder (0.31-0.50), kidney and renal pelvis (0.41-0.59), thyroid (0.73-0.81), non-Hodgkin's lymphomas (0.37-0.63), Hodgkin's disease (0.61-0.81), and leukaemias (0.27-0.39). Survival for all cancers and both sexes combined, rose from 0.51-0.64 (0.57 for males, 0.71 for females). No appreciable change in survival was observed for cancers of oesophagus, liver, gallbladder, pancreas, larynx, cervix uteri, brain, multiple myeloma, as well as unidentified or unknown origin neoplasms. Conclusions Survival estimates for most cancer sites are comparable to the US SEER dataset, and their pattern of trends are discussed in terms of improved diagnosis and treatment for various neoplasms